代谢组学在冠状动脉粥样硬化性心脏病中的研究进展  

Research progress on metabonomics of coronary heart disease

作　　者：王治财 仓彦[2] WANG Zhicai;CANG Yan(School of Medicine,Anhui University of Science and Technology,Huainan,Anhui 232000,China;Department of Cardiology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China)

机构地区：[1]安徽理工大学医学院,安徽淮南232000 [2]同济大学附属上海市第十人民医院心内科,上海200072

出　　处：《安徽医药》2023年第7期1293-1297,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：冠状动脉粥样硬化性心脏病(简称冠心病)是最常见的临床心血管疾病,也是世界范围内诱导人死亡的最主要疾病。冠心病病人体液中代谢物浓度的变化反映了冠心病的发病和发展过程,也是心脏功能障碍的生物学特征,这促使人们利用代谢组学探索新的生物标志物来更好地阐明冠心病的机制。代谢组学在冠心病中的应用有助于冠心病的早期诊断,个体化治疗和预测其预后。该研究简要阐述了国内外冠心病代谢组学的研究现状,利用代谢组学为冠心病机制的进一步研究提供依据。Coronary heart disease(CHD)is the most common clinical cardiovascular disease,and it is also the main serious disease inducing human death all over the world.The changes of metabolite concentrations in body fluids of patients with coronary heart disease reflect the pathogenesis and development of coronary heart disease,and are also the biological characteristics of cardiac dysfunction.Metabonomics research can find new biomarkers to better clarify the mechanism of coronary heart disease,which is helpful to the early diagnosis,individualized treatment and prognosis of coronary heart disease.Therefore,the study of metabonomics in coronary heart disease is of great significance,and it is also a new field in system biology.This paper briefly describes the research status of metabonomics of coronary heart disease at home and abroad,in order to provide basis for further study of the mechanism of coronary heart disease by using metabonomics.

关 键 词：冠状动脉粥样硬化性心脏病(冠心病) 代谢组学 生物标志物 肌酸激酶 脂蛋白类 气相色谱-质谱法 

分 类 号：R541.4[医药卫生—心血管疾病]